Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.

Schiano C, Soricelli A, De Nigris F, Napoli C.

Expert Rev Clin Immunol. 2019 Mar;15(3):289-301. doi: 10.1080/1744666X.2019.1561283. Epub 2019 Jan 2.

PMID:
30570412
2.

Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy.

Leibfarth S, Winter RM, Lyng H, Zips D, Thorwarth D.

Clin Transl Radiat Oncol. 2018 Sep 20;13:29-37. doi: 10.1016/j.ctro.2018.09.002. eCollection 2018 Nov. Review.

3.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Chakravarty R, Siamof CM, Dash A, Cai W.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018. Review.

4.

Clinical translation of immunoliposomes for cancer therapy: recent perspectives.

Wang D, Sun Y, Liu Y, Meng F, Lee RJ.

Expert Opin Drug Deliv. 2018 Sep;15(9):893-903. doi: 10.1080/17425247.2018.1517747. Epub 2018 Sep 12. Review.

PMID:
30169978
5.

The Role of Magnetic Resonance Imaging in Brachytherapy.

Tharmalingam H, Alonzi R, Hoskin PJ.

Clin Oncol (R Coll Radiol). 2018 Nov;30(11):728-736. doi: 10.1016/j.clon.2018.07.024. Epub 2018 Jul 31.

PMID:
30075902
6.

Multiparametric (mp) MRI of prostate cancer.

Kumar V, Bora GS, Kumar R, Jagannathan NR.

Prog Nucl Magn Reson Spectrosc. 2018 Apr;105:23-40. doi: 10.1016/j.pnmrs.2018.01.001. Epub 2018 Jan 31. Review.

PMID:
29548365
7.

Concomitant bladder cancer and prostate cancer: challenges and controversies.

Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R.

Nat Rev Urol. 2017 Oct;14(10):620-629. doi: 10.1038/nrurol.2017.124. Epub 2017 Aug 16. Review.

PMID:
28813037
8.

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.

Kallur KG, Ramachandra PG, Rajkumar K, Swamy SS, Desai I, Rao RM, Patil SG, Sridhar PS, Madhusudhan N, Krishnappa RS, Bhadrasetty V, Kumara HM, Santhosh SD, Ajaikumar BS.

Indian J Nucl Med. 2017 Apr-Jun;32(2):110-117. doi: 10.4103/0972-3919.202255.

9.

Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow.

Blanchard P, Ménard C, Frank SJ.

Brachytherapy. 2017 Jul - Aug;16(4):734-742. doi: 10.1016/j.brachy.2016.11.012. Epub 2017 Jan 30.

10.

64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer.

Chakravarty R, Chakraborty S, Dash A.

Mol Pharm. 2016 Nov 7;13(11):3601-3612. Epub 2016 Oct 14. Review.

PMID:
27709959
11.

PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management.

Mahajan A, Azad GK, Cook GJ.

PET Clin. 2016 Jul;11(3):305-18. doi: 10.1016/j.cpet.2016.02.003. Epub 2016 Mar 23. Review.

PMID:
27321034
12.

The role of medical physics in prostate cancer radiation therapy.

Fiorino C, Seuntjens J.

Phys Med. 2016 Mar;32(3):435-7. doi: 10.1016/j.ejmp.2016.03.020. Epub 2016 Apr 16.

PMID:
27095755
13.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.

Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.

PMID:
26850970
14.

Current Status of Hybrid PET/MRI in Oncologic Imaging.

Rosenkrantz AB, Friedman K, Chandarana H, Melsaether A, Moy L, Ding YS, Jhaveri K, Beltran L, Jain R.

AJR Am J Roentgenol. 2016 Jan;206(1):162-72. doi: 10.2214/AJR.15.14968. Epub 2015 Oct 22. Review.

15.

The role of MRI in active surveillance for men with localized prostate cancer.

Recabal P, Ehdaie B.

Curr Opin Urol. 2015 Nov;25(6):504-9. doi: 10.1097/MOU.0000000000000221. Review.

PMID:
26372037
16.

In-vitro and in-vivo diagnostic techniques for prostate cancer: a review.

McClure P, Elnakib A, Abou El-Ghar M, Khalifa F, Soliman A, El-Diasty T, Suri JS, Elmaghraby A, El-Baz A.

J Biomed Nanotechnol. 2014 Oct;10(10):2747-77. Review.

PMID:
25992417
17.

Prostate MRI can reduce overdiagnosis and overtreatment of prostate cancer.

Rosenkrantz AB, Taneja SS.

Acad Radiol. 2015 Aug;22(8):1000-6. doi: 10.1016/j.acra.2015.02.006. Epub 2015 Mar 17. Review.

PMID:
25791578
18.

Multiparametric magnetic resonance imaging of the prostate: technical aspects and role in clinical management.

Costa DN, Pedrosa I, Roehrborn C, Rofsky NM.

Top Magn Reson Imaging. 2014 Aug;23(4):243-57. doi: 10.1097/RMR.0000000000000027. Review.

PMID:
25099562
19.

Methods for nuclei detection, segmentation, and classification in digital histopathology: a review-current status and future potential.

Irshad H, Veillard A, Roux L, Racoceanu D.

IEEE Rev Biomed Eng. 2014;7:97-114. doi: 10.1109/RBME.2013.2295804. Review.

PMID:
24802905
20.

Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM.

Transl Oncol. 2014 Feb 1;7(1):120-9. eCollection 2014 Feb.

Supplemental Content

Loading ...
Support Center